Hedge fund Starboard Value has taken a stake in Kenvue, the consumer products company behind well-known brands such as Band-Aid, Listerine, and Tylenol, which went public last year. While the exact size of Starboard’s stake remains unclear, the move reflects the hedge fund’s interest in improving Kenvue’s performance after its stock price dropped 18% since its public listing in May 2023. Kenvue’s shares recently closed at $21.72, giving the company a market value of $41 billion.
Formerly a division of Johnson & Johnson, Kenvue has struggled to maintain investor confidence, with its stock price declining since its IPO. Starboard Value is reportedly encouraging the company to review how it positions and prices its brands to bolster its overall performance. This potential shift in strategy could involve a reassessment of product pricing and brand placement in the market.
The development comes as Starboard prepares for the upcoming 13D Monitor Active-Passive Investor Summit, where Jeffrey Smith, the hedge fund’s chief investment officer, is expected to share investment ideas. Starboard is also expected to reveal its new investment in pharmaceutical giant Pfizer at the event, which is estimated to be around $1 billion. The hedge fund has expressed its intention for Pfizer to focus on improving its financial performance, with meetings already having taken place between Starboard’s leadership and Pfizer CEO Albert Bourla, as well as the company’s lead independent director.
Pfizer, renowned for delivering the world’s first COVID-19 vaccine, has seen its stock price fall nearly 50% since 2021, a period marked by unprecedented demand for the vaccine. Starboard’s investment indicates confidence in the pharmaceutical giant’s ability to rebound, particularly as it looks to navigate the post-pandemic market environment.
Starboard’s recent moves in both Kenvue and Pfizer highlight the hedge fund’s strategy of identifying companies with strong brand presence or potential for growth and working to improve their financial outlook. Whether through brand repositioning or operational improvements, Starboard is clearly focused on driving better performance from its latest investments. With Kenvue under pressure to reverse its declining stock price and Pfizer seeking to recover from a post-COVID slump, these investments underscore the hedge fund’s active approach to boosting corporate value.
READ MORE: